Evidence map›Paper›PMID 39613819›Full record

ArticleScientific reports2024

Interpreting the function of cell penetrating peptide (RGD) in drug transport to the cell membrane: a computational approach.

Fatemeh Talaei, Farzaneh Farzad

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fatemeh TalaeiDepartment of Chemistry, University of Birjand, Birjand, Iran.
Farzaneh FarzadDepartment of Chemistry, University of Birjand, Birjand, Iran. ffarzad5487@birjand.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbon nanotubes (CNT) have unique properties that make them an excellent option for use as drug carriers. However, to make them safe for the human body, their walls are typically coated with a layer of peptide, which also helps to neutralize their toxicity. Additionally, a specific peptide sequence can be used to deliver therapeutic agents exclusively to cancer cells. In recent years, considerable progress has been made in the development of drug delivery systems (DDS) for drug delivery by computer-assisted. The present study inquires about the loading of ketoprofen (Ket) and naproxen (Nap) conjugated with RGD peptide sequence on CNT and its interaction with the double-layer membrane using the molecular dynamics (MD) simulation method. The obtained results show that the investigated complexes often interact through van der Waals and π-π interactions. Energy values for ketoprofen and naproxen with CNT were evaluated - 270.63 and - 195.8 kJ/mol, respectively. The results of the physical adsorption of the complexes on the membrane surface show that the CNT-KRG and CNT-NRG complexes spontaneously diffuse into the biological membrane. In addition, the study of the interaction energy values ​​of these two complexes with the membrane shows that the van der Waals energy plays a significant role in the stability of the systems. On the other hand, the study of the interaction between the drug-CNT complex and the membrane surface shows that the drug can easily penetrate the membrane in the presence of the peptide sequence and the carrier.

Indexed as

Cell MembraneCell-Penetrating PeptidesMolecular Dynamics SimulationNaproxenOligopeptidesBiological TransportDrug CarriersDrug Delivery SystemsHumansKetoprofenarginyl-glycyl-aspartic acidCell-Penetrating PeptidesDrug CarriersKetoprofenNaproxenOligopeptidesCarbon nanotubesDrug delivery systemsMD simulationMetadynamicNaproxen

Identifiers

PMID39613819
PMCPMC11607415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.